Defendant
2 cases as defendant.
I'll research Amneal Pharmaceuticals to verify its profile.
Let me verify the litigation context.
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) is a publicly traded, founder-controlled pharmaceutical company headquartered in Bridgewater, New Jersey, and founded in 2002 by brothers Chirag and Chintu Patel, who remain co-CEOs and dominant voting shareholders. It reports roughly 8,300–8,500 employees and FY2025 net revenue of $3.02 billion (up 8% year over year), with operations principally in the U.S., India, and Ireland.
Amneal develops, manufactures, markets, and distributes medicines through three segments: Affordable Medicines (retail generics, injectables, and biosimilars), Specialty (branded CNS and endocrine products including CREXONT, RYTARY, UNITHROID, and the BREKIYA dihydroergotamine autoinjector), and AvKARE, a distributor of pharmaceuticals and medical supplies to U.S. federal agencies, primarily the Department of Defense and Department of Veterans Affairs. It is one of the larger U.S. generics manufacturers and also operates contract manufacturing and biosimilar programs.
Litigation posture: Amneal is an operating company appearing solely as a defendant — 0 plaintiff cases, 1 defendant case in the tracked data. Its single tracked matter is a branded-versus-generic Hatch-Waxman dispute, not a patent-assertion-entity suit. Venue is the District of Delaware, the standard forum for ANDA litigation, not a plaintiff-friendly NPE venue such as the Eastern District of Texas.
Notable case: Neurelis, Inc. v. Amneal Pharmaceuticals (D. Del., filed 2026-03-11). Neurelis markets VALTOCO (diazepam nasal spray) for seizure clusters. The suit concerns Amneal's Abbreviated New Drug Application No. 219109 covering generic 7.5 mg/spray and 10 mg/spray diazepam nasal spray, and asserts U.S. Patent No. 12,521,400 ("Administration of Benzodiazepine Compositions") — part of the same patent family Neurelis has asserted against other ANDA filers (Padagis, Lupin) in parallel Delaware actions. This is routine generic-entry exposure rather than evidence of assertive patent monetization.
Note: any characterization of the case's merits is outside this profile; the filing date and posture above reflect the tracked record.
Neurelis, Inc.'s ANDA suit against Amneal Pharmaceuticals. Google Patents' litigation links point to this docket and 1:25-cv-00821, while aggregator pages list the '664 patent among the consolidated family; no individual docket confirmation is provided.
Celgene sued Amneal Pharmaceuticals in D.N.J. (2:24-cv-00500). The patents-in-suit were U.S. 7,465,800 and 7,855,217, and a consent judgment was entered on February 5, 2024, with a permanent injunction barring Amneal's ANDA No. 216213 until expiration.